Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation
about
FAM83A confers EGFR-TKI resistance in breast cancer cells and in miceThe SH3 domain of p56lck is involved in binding to phosphatidylinositol 3'-kinase from T lymphocytesA tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activationExpression and characterization of the p85 subunit of the phosphatidylinositol 3-kinase complex and a related p85 beta protein by using the baculovirus expression systemThe docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathwayThe somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapesThe p85 subunit of phosphoinositide 3-kinase is associated with beta-catenin in the cadherin-based adhesion complexEpidermal growth factor-induced phosphatidylinositol 3-kinase activation and DNA synthesis. Identification of Grb2-associated binder 2 as the major mediator in rat hepatocytesA novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signalingRegulation of PI3K/Akt dependent apoptotic markers during b virus infection of human and macaque fibroblasts.Cooperation of Src homology domains in the regulated binding of phosphatidylinositol 3-kinase. A role for the Src homology 2 domain.Structure of 85 kDa subunit of human phosphatidylinositol 3-kinase analyzed by using monoclonal antibodies.The SH2- and SH3-containing Nck protein transforms mammalian fibroblasts in the absence of elevated phosphotyrosine levels.Mutations in the SH3 domain of the src oncogene which decrease association of phosphatidylinositol 3'-kinase activity with pp60v-src and alter cellular morphology.Interleukin 2- and polyomavirus middle T antigen-induced modification of phosphatidylinositol 3-kinase activity in activated T lymphocytes.The first long-lived mutants: discovery of the insulin/IGF-1 pathway for ageingInteraction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptorsEpidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysTissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.Thrombin-stimulated immunoprecipitation of phosphatidylinositol 3-kinase from human platelets.Natural biology of polyomavirus middle T antigen.Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathwayHeterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors.Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.A minor tyrosine phosphorylation site located within the CAIN domain plays a critical role in regulating tissue-specific transformation by erbB kinaseSignal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinaseIntegrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancerRecruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinaseE-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1)Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members.ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factorModulation of erbB kinase activity and oncogenic potential by single point mutations in the glycine loop of the catalytic domain.The E5 gene product of rhesus papillomavirus is an activator of endogenous Ras and phosphatidylinositol-3'-kinase in NIH 3T3 cells.Interactions between SH2 domains and tyrosine-phosphorylated platelet-derived growth factor beta-receptor sequences: analysis of kinetic parameters by a novel biosensor-based approachTransformation-defective mutants of polyomavirus middle T antigen associate with phosphatidylinositol 3-kinase (PI 3-kinase) but are unable to maintain wild-type levels of PI 3-kinase products in intact cellsThe Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor.Epidermal growth factor-stimulated calcium ion transients in individual A431 cells: initiation kinetics and ligand concentration dependence.Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase.
P2860
Q24296333-0E960D9E-8867-49F0-A695-1BB1B56A222AQ24304668-D64376D0-10EE-4E35-803B-EF2866C39118Q24310428-7B773AD5-4288-40E5-ACD0-BB21D4E7DA09Q24314456-CFE3E8AF-6B8E-4C19-99C8-870981294D9DQ24527428-21B16D71-F18E-423C-8415-03F1FF3B2BC1Q24799816-67A63B52-BD96-401E-86F7-C38CDD1A4726Q28275430-4EDAA800-985A-4ED6-9118-DBC59169691DQ28364575-25CD1127-B915-428F-B133-21B9BD4CB88CQ28571849-D1004060-B4B2-4164-ADA6-0B3327D00178Q28609913-DC435B1B-222A-4F0C-939B-E23A1289E7F6Q30100963-4850826A-0EAF-4880-90DA-706F54DB01B6Q30193526-BD438DFC-B63A-4B4C-8BBC-47D252EA0547Q30195126-DAB5CD02-6212-424C-A0DC-3DCD343B752EQ30195199-7369D72E-9CB0-438F-BCF3-F909F0FDB13CQ30195440-DC4D979A-F64E-4201-9A95-EFD160385DFDQ30450318-CC2DC1CF-72CB-4973-B412-C723F42C291BQ30497647-5BDB6341-27F1-48C2-9774-E25A88F67526Q31169174-0108C34C-CE1F-4FDC-95E3-AAD9892A21F5Q33737298-266D522C-47B7-48FE-BEAA-48DBC2E9B832Q33905827-583B65FF-7066-433A-8A05-ECAC3772A2C7Q33918164-B5540DC3-13E5-47EE-9304-B5E1FC62C8FDQ33948870-218DE714-10EC-4E98-A5E2-4A9E5E0D44FDQ34048106-8250FA3B-2FE7-4DB0-B536-66A8883D03A6Q35054357-BF49D6FB-535F-420A-9271-9FFDA43A355DQ35769059-BBD07099-BD83-4057-8EB9-E22816EBD650Q35800467-12A69EDD-3E90-406A-943C-1F593D7CE54EQ35832783-E4019D39-7F8A-4869-B209-CCC8E1014BC4Q35929162-EF9D5DC2-008C-492B-BA9A-CB5AA512E99BQ36092726-3C769F14-73EE-4E0B-9430-DB9D8B7A2ACBQ36235312-6EA258AF-B0D8-4BBD-950B-5D881660D70AQ36256290-8ACD629D-7E0C-48F1-8738-2959E0E0062CQ36643816-38A7F252-FE8C-406A-8F5F-BA5DFEF80168Q36653753-C378B1A5-5B40-44D7-BE2A-FE270F9FA124Q36667993-898D2611-B1EF-4812-AE97-6BAA32C524D8Q36685093-A6428790-4406-4D05-843D-C186BBB2A45CQ36686508-DB072F64-9868-413A-B139-AEE9DF76ABB7Q36693102-24A3107C-089E-41E1-B98A-ABB291CE59C4Q36695763-42CE2CA4-54AA-4AAD-9DC9-2C2D8676969BQ36746002-660CFF08-19AD-43CC-8711-47B98C10D3A1Q36794090-E6A53BA2-C6D1-4D35-9381-D95C1A548CE0
P2860
Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation
description
1990 nî lūn-bûn
@nan
1990 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Activated type I phosphatidyli ...... ptor following EGF stimulation
@ast
Activated type I phosphatidyli ...... ptor following EGF stimulation
@en
Activated type I phosphatidyli ...... th the epidermal growth factor
@nl
type
label
Activated type I phosphatidyli ...... ptor following EGF stimulation
@ast
Activated type I phosphatidyli ...... ptor following EGF stimulation
@en
Activated type I phosphatidyli ...... th the epidermal growth factor
@nl
prefLabel
Activated type I phosphatidyli ...... ptor following EGF stimulation
@ast
Activated type I phosphatidyli ...... ptor following EGF stimulation
@en
Activated type I phosphatidyli ...... th the epidermal growth factor
@nl
P2093
P2860
P356
P1476
Activated type I phosphatidyli ...... ptor following EGF stimulation
@en
P2093
P2860
P304
P356
10.1073/PNAS.87.10.3816
P407
P577
1990-05-01T00:00:00Z